Research Paper Volume 14, Issue 12 pp 5131—5152
Exploring immune-related signatures for predicting immunotherapeutic responsiveness, prognosis, and diagnosis of patients with colon cancer
Figure 5. Comparison of the expression levels of the immune checkpoints and their ligands between the high-risk score group and low-risk score group. The expression of PD-1 (A), PD-L1 (B), CTLA-4 (C), HAVCR2 (D), LAG3 (E), or TIGIT (F).